| MediWound Ltd.: Undervalued High-Growth Potential |
I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue growth, while EscharEx's promising phase 3 trial could unlock a huge chronic wound market. The company's strong balance sheet, with ample cash and minimal debt, provides a solid runway for R&D and shields against economic headwinds. |
seekingalpha.com |
2025-05-16 14:34:43 |
Czytaj oryginał (ang.) |
| MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers |
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® |
globenewswire.com |
2025-05-13 11:30:00 |
Czytaj oryginał (ang.) |
| MediWound to Report First Quarter 2025 Financial Results |
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time |
globenewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| MediWound to Present New EscharEx® Data at Leading Wound Care Conferences |
Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL ® , and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30–May 3 in Grapevine, Texas. |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript |
MediWound Ltd. (NASDAQ:MDWD ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President, Strategy & Corporate Development Conference Call Participants Josh Jennings - Cowen Francois Brisebois - Oppenheimer RK - H.C. |
seekingalpha.com |
2025-03-19 14:10:18 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates |
MediWound (MDWD) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-03-19 11:10:24 |
Czytaj oryginał (ang.) |
| MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. |
globenewswire.com |
2025-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| MediWound to Report Fourth Quarter and Full Year 2024 Financial Results |
YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care |
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. |
globenewswire.com |
2025-02-25 10:00:00 |
Czytaj oryginał (ang.) |
| MediWound to Present at the 45th Annual TD Cowen Health Care Conference |
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| MediWound to launch Phase III trial for venous leg ulcers |
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. |
reuters.com |
2025-02-12 10:12:14 |
Czytaj oryginał (ang.) |
| MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers |
Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure |
globenewswire.com |
2025-02-12 09:00:00 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains? |
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-27 09:36:06 |
Czytaj oryginał (ang.) |
| MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript |
MediWound Ltd. (NASDAQ:MDWD ) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President, Strategy & Corporate Development Conference Call Participants Josh Jennings - Cowen Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2024-11-26 15:46:12 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates |
MediWound (MDWD) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.24 per share a year ago. |
zacks.com |
2024-11-26 11:16:11 |
Czytaj oryginał (ang.) |
| MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update |
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cas h Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| MediWound Is A Healthy Investment |
MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling in price YTD, and is backed by a healthy mix of institutional and private investors. |
seekingalpha.com |
2024-10-29 12:49:41 |
Czytaj oryginał (ang.) |
| MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers |
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes |
globenewswire.com |
2024-10-10 11:00:00 |
Czytaj oryginał (ang.) |
| MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns |
Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages |
globenewswire.com |
2024-08-15 20:15:00 |
Czytaj oryginał (ang.) |
| MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript |
MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day and welcome to MediWound's Second Quarter 2024 Earnings Call. |
seekingalpha.com |
2024-08-14 19:00:07 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates |
MediWound (MDWD) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2024-08-14 13:15:55 |
Czytaj oryginał (ang.) |
| MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update |
Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference C all T oday, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-08-14 11:00:00 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release |
MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-07 15:06:25 |
Czytaj oryginał (ang.) |
| MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) |
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients |
globenewswire.com |
2024-08-05 11:30:00 |
Czytaj oryginał (ang.) |
| MediWound to Report Second Quarter 2024 Financial Results |
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time |
globenewswire.com |
2024-08-02 12:00:00 |
Czytaj oryginał (ang.) |
| Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect? |
The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-07-31 14:56:10 |
Czytaj oryginał (ang.) |
| MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers |
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue |
globenewswire.com |
2024-07-29 12:00:00 |
Czytaj oryginał (ang.) |
| MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program |
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) |
globenewswire.com |
2024-07-16 11:30:00 |
Czytaj oryginał (ang.) |
| Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd |
GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). |
prnewswire.com |
2024-07-15 11:32:00 |
Czytaj oryginał (ang.) |
| MediWound Announces $25 Million Strategic Private Placement Financing |
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment |
globenewswire.com |
2024-07-15 11:00:00 |
Czytaj oryginał (ang.) |
| MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript |
MediWound Ltd. (NASDAQ:MDWD ) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy, Corporate Development Daniel Ferry - Managing Director, LifeSci Advisors Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day! |
seekingalpha.com |
2024-05-29 15:35:07 |
Czytaj oryginał (ang.) |
| MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates |
MediWound (MDWD) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago. |
zacks.com |
2024-05-29 13:16:04 |
Czytaj oryginał (ang.) |
| MediWound Reports First Quarter 2024 Financial Results and Provides Company Update |
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |